OCUMENSION THERAPEUTICS

Insiders Ocumension Therapeutics

Equities

1477

KYG674111011

Market Closed - Hong Kong S.E. Other stock markets 09:08:22 10/05/2024 BST			5-day change	1st Jan Change
6.79 ^HKD	-2.86%		-8.86%	+1.65%

04-15	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
04-15	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	12-08	MT
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023	29/09/23	CI
Ocumension Therapeutics Announces Executive Changes	15/06/22	CI
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee	08/04/22	CI
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee	31/03/22	CI
Ocumension Therapeutics Announces Re-Designation of Executive Directors as Non-Executive Directors	20/07/21	CI
Ocumension Therapeutics Announces Board Changes	19/03/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer